Oxaloacetate Supplement Shows Promise for Cancer-Related Cognitive Impairment in Preliminary Study

A recent preliminary clinical study indicates that the dietary supplement oxaloacetate may help improve cancer-related cognitive impairment, often referred to as chemo brain or brain fog, in breast cancer survivors. Published in JCO Oncology Advances, the small single-arm trial evaluated the effects of the glutamate regulator on patients experiencing persistent cognitive difficulties following cancer treatment.

Understanding Cancer-Related Cognitive Impairment

Post-treatment cognitive impairment is a frequent and challenging issue for many individuals who undergo cancer therapies, particularly breast cancer survivors. While the exact biological mechanisms behind the condition remain unclear, researchers note that it became more prevalent following the widespread adoption of adjuvant chemotherapy regimens. Some therapeutic agents cross the blood-brain barrier and can induce neurotoxic effects, impacting executive function, memory, and processing speed. Non-pharmacological approaches, such as exercise, cognitive-behavioral strategies, and management of anxiety or depression, have historically formed the bulk of supportive interventions.

Study Design and Preliminary Findings

Led by Patricia Ganz, MD, of UCLA Health, and her colleagues, the prospective study investigated the oral administration of oxaloacetate at a dose of 500 mg twice daily for eight weeks. Eligible participants were between one and five years removed from active cancer treatment and demonstrated moderately severe cognitive impairment based on standardized questionnaires. Out of 18 enrolled patients, 16 completed the evaluation. Key findings from the preliminary trial include:

• All evaluable patients showed statistically significant and clinically meaningful improvements in perceived cognitive function after eight weeks of treatment.
• The mean score on the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) perceived cognitive impairment scale almost doubled, moving the cohort from an impaired baseline to within the normal range.
• Secondary endpoints revealed significant improvements in fatigue and physical functioning, alongside a notable trend toward reduced insomnia.
• Neuropsychological testing confirmed measurable enhancements in executive function and processing speed.

Safety and Limitations

Regarding safety, the intervention was generally well tolerated. The most commonly reported adverse events included mild gastrointestinal symptoms such as indigestion, bloating, constipation, diarrhea, and nausea. Two participants discontinued the regimen due to gastrointestinal side effects, and no serious adverse events were documented.

Researchers and independent experts emphasized important limitations of the study. Most notably, the trial lacked a control group and included a very small sample size. Halle Moore, MD, of the Cleveland Clinic, who was not involved in the research, noted that while the patient-perceived cognitive gains and improvements in fatigue are impressive, the lack of a placebo-controlled group necessitates cautious interpretation. Investigators approached the initial data with skepticism, utilizing a two-step design to quickly gauge outcomes before planning the next phase of research.

Next Steps in Research

Given the scarcity of established pharmacological treatments for cancer-related cognitive impairment, the preliminary outcomes have paved the way for more rigorous investigation. A larger, randomized, placebo-controlled phase II study of oxaloacetate is expected to begin patient enrollment before the end of the year to further establish safety and efficacy compared to a control group.